Purpose: Various forms of local haemostats are increasingly used routinely in surgical procedures. Our work is the first comparison of the efficacy and safety of non-regenerated and regenerated oxidized cellulose based fibrous haemostats. Methods: The haemostatic efficacy and safety of fibrous haemostats based on ONRC and ORC were compared in a randomized multicenter study. The primary endpoint was successful haemostasis within 3 minutes of application and no need for surgical revision within 12 hours after the procedure for recurrent bleeding. Results: There was a significant difference in the rate of successful haemostasis in 3 minutes that was achieved in 82% and 55% in the ONRC and ORC groups, respectively (confidence interval 99%; p = ...
Background/Aims: Fibrocaps is a dry powder fibrin sealant containing human plasma-derived fibrinogen...
BACKGROUND: This Phase 3, international, randomized, single-blind, controlled trial (FINISH-3) compa...
Background This Phase 3, international, randomized, single-blind, controlled trial (FINISH-3) compar...
OBJECTIVE: To compare the efficacy and safety of HemoStyp (United Health Products, US), a neutralise...
Melinda H MacDonald, Allen Y Wang, Jeffrey W Clymer, Richard W Hutchinson, Richard Ko...
The bleeding of intraoperative period is one of the actual problem in surgery. There aren’t any univ...
Background Local hemostatic agents have a role in limiting bleeding complications associated with li...
BACKGROUND: Bleeding during hepatic surgery is associated with prolonged hospitalization and increas...
Hypothesis :An investigational surgical fibrin sealant (Crosseal; American Red Cross, Washington, DC...
Background: Fibrocaps, a ready-to-use, dry-powder fibrin sealant containing human plasma-derived thr...
Abstract Background Haemostasis in liver surgery remains a challenge despite improved resection tech...
Background: Bone wax (BW) or oxidized regenerated cellulose (ORC) concomitant with electrocoagulatio...
Background: Fibrocaps, a ready-to-use, dry-powder fibrin sealant containing human plasma-derived thr...
BACKGROUND: This Phase 3, international, randomized, single-blind, controlled trial (FINISH-3) compa...
AbstractPurpose: Currently available hemostatic pads are effective in treating oozing bleeds, but ot...
Background/Aims: Fibrocaps is a dry powder fibrin sealant containing human plasma-derived fibrinogen...
BACKGROUND: This Phase 3, international, randomized, single-blind, controlled trial (FINISH-3) compa...
Background This Phase 3, international, randomized, single-blind, controlled trial (FINISH-3) compar...
OBJECTIVE: To compare the efficacy and safety of HemoStyp (United Health Products, US), a neutralise...
Melinda H MacDonald, Allen Y Wang, Jeffrey W Clymer, Richard W Hutchinson, Richard Ko...
The bleeding of intraoperative period is one of the actual problem in surgery. There aren’t any univ...
Background Local hemostatic agents have a role in limiting bleeding complications associated with li...
BACKGROUND: Bleeding during hepatic surgery is associated with prolonged hospitalization and increas...
Hypothesis :An investigational surgical fibrin sealant (Crosseal; American Red Cross, Washington, DC...
Background: Fibrocaps, a ready-to-use, dry-powder fibrin sealant containing human plasma-derived thr...
Abstract Background Haemostasis in liver surgery remains a challenge despite improved resection tech...
Background: Bone wax (BW) or oxidized regenerated cellulose (ORC) concomitant with electrocoagulatio...
Background: Fibrocaps, a ready-to-use, dry-powder fibrin sealant containing human plasma-derived thr...
BACKGROUND: This Phase 3, international, randomized, single-blind, controlled trial (FINISH-3) compa...
AbstractPurpose: Currently available hemostatic pads are effective in treating oozing bleeds, but ot...
Background/Aims: Fibrocaps is a dry powder fibrin sealant containing human plasma-derived fibrinogen...
BACKGROUND: This Phase 3, international, randomized, single-blind, controlled trial (FINISH-3) compa...
Background This Phase 3, international, randomized, single-blind, controlled trial (FINISH-3) compar...